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Abstract  
Since the beginning of the 1980s, together with the development of biotechnology research and 
industry, new associations that in many cases join members from industry, academia and 
administration have been established in Japan. In this paper I argue that the theory of 
neocorporatism fails to explain the creation of associations with such heterogeneous membership. 
Instead, applying Jessop’s governance theory I propose the analysis of the relationship between 
associations’ functions and the characteristics of biotechnology, in order to explain this kind of 
associations. In this paper I analyze the characteristics of biotechnology and policies for 
biotechnology, and the imperative conditions they involve for the development of bio-industry. 
Then I analyze associations’ activities in Japan. I conclude that associations in the Japanese 
bio-industry have three main functions: adaptation of the economic system to the imperative 
conditions of biotechnology, networks construction, and collective learning. 
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1 Introduction 
 
Since the 1970s the expenditure of developed countries in scientific and technological 
research has been increasing, occupying a growing part of their economies. Japan’s 
research expenditure steadily increased from less than ¥ 5 billion in 1975 to ¥ 16 billion in 
the year 2000. The US expenditure increased from about ¥ 5 billion in 1975 to ¥ 28 billion 
in the year 2000. Considering the rate that research expenditure represents on the GNP, 
in Japan it grew from the 2.0% in 1975 to the 3.12% in the year 2000. Also in the US it 
grew from the 2.2% in 1975 to the 2.65 in 2000 (MET, 2001). Also the research personnel 
have increased, growing the proportion in the labor force that it represents. Thus, in 
Japan it grew from near 65 researchers per 10,000 workers in 1980 to 109.3 in the year 
2000, and in the US from 60 in 1980 to 73.8 in 1996 (MET, 2001). In addition, the weight 
of research in the industry has grown. In Japan the percentage of research expenditure 
on the total sales of private companies grew constantly from 1985 to 1992, from the 2.31% 
to the 2.83%.1) Although it has slightly fallen to the 2.72% in 1994, due to the economic 
crisis of the 1990s, it is still higher than in the 1980s (JETRO, 1997). This increasing 
presence of technology and science in the economy and industry reflects the importance of 
the introduction of innovations into industry in form of new products and processes, and 
improvement of the previous ones. 
  The industry that applies biotechnology, either in its products or in its processes, is one 
example of the process of technologization of industry. The biotechnology related market 
has grown in Japan from ¥ 200,000 million in 1989 to ¥ 1,179,470 million in 1998 (METI, 
2001a).  Together with the development of bio-industry in Japan, associations of 
companies, researchers and public officials, have been established. At present, in Japan 
there are 14 bio-industry related associations, of which 5 are nation-wide associations and 
9 are regional associations. Their mixed membership makes these associations different 
from the trade associations in other industrial sectors, which are organized as 
representatives of the companies in those sectors. Theories of interests groups, which 
have theoretically and empirically analyzed trade associations, are not able to explain the 
                                                          
1) The industries with a bigger proportion of research expenditure on the total sales in 1994 were 
pharmaceuticals (7.79%), electrical machinery (5.86%), precision instruments (5.51%), and chemicals 
and textiles （4.24%) (JETRO, 1997). 
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composition of these associations. Considering the theory of neocorporatism, I argue that 
the problem is that this theory is too much centered on authority relations. I argue that 
instead, the functions of the associations to satisfy the imperative conditions imposed by 
the technical characteristics of bio-industry are an important explicative element. For 
this, I analyze what characteristics bio-industry and its related policy-making have. Then 
I analyze the activities of associations and their relation with those characteristics. 
2. Theoretical approaches 
2.1. Theory of neocorporatism 
The theory of neocorporatism (Schmitter, 1979; Schmitter and Streeck, 1981; Streeck and 
Schmitter, 1985) assumes that companies in an industrial sector get organized into 
business associations due to two associative logics. One is the logic of membership. 
According to this logic companies establish associations with other companies sharing the 
same interests, in order to promote them in front of the state and other organizations with 
conflicting interests.  If this logic dominates the collective action, the system of 
associations will become a pluralist system in which many associations promoting narrow 
interests in conflict compete with each other for public policies. 
  However, in many European countries and in Japan, the action of the state involves 
the action of a second associative logic, the logic of influence. According to this logic the 
state selects and promotes the association that wants as representative of a specific 
industry. Thus, the logic of influence involves that associations behave within the limits 
of the game rules that the state is willing to accept. It also involves that selected 
associations have a privileged access to the state, therefore not selected associations merge 
with them or lose their membership. 
  The interaction between the logic of membership, which pushes for disintegration, and 
the logic of influence, which pushes for integration, produces that associations integrate in 
pyramidal structures, becoming different sections of a larger association that represents 
the whole industrial sector in front of the state. In this association, the sections that 
represent conflicting interests negotiate in the association. According to this theory the 
plurality of conflicting interests is a kind of complexity, and the integration of conflicting 
interests in a unified organizational structure, which manages them and “imposes” on 
them solutions for the issue at stake, is what the authors call organized complexity. 
Associations can manage their members’ conflicting interests because associations’ 
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bureaucracy gains autonomy from the membership and gets authority from the state to 
participate in policy-making, including policy formation and implementation, becoming the 
representatives of the companies of the same industrial sector. With this, associations 
undertake the function of maintaining the social order. 
  However, bio-industry associations' membership in many cases is composed by actors 
with a different nature, including researchers, public officials, and companies from 
different industrial sectors. And, as I will show in this paper, the main function of these 
associations is to create connections between those agents, and to provide them with 
forums where they can interact and cooperate. Thus, the neocorporatist explanation is 
not suitable enough for bio-industry associations. 
 
2.2. Governance theory 
The governance theory proposed by Jessop has a different conception of complexity. This 
concept of complexity is more based on the limits of knowledge than on conflicting interests. 
For Jessop, economic globalization and technological change have produced an increase in 
the diffusion of resources in the society and an increase in the autonomy of the actors who 
hold them. But, these same processes have also increased the interdependences among 
the different actors. Thus, to solve a problem it is necessary the cooperation of different 
actors in order to understand the causal relations and to coordinate the actions of different 
actors to create a strategy to solve the problem. This process is what Jessop calls 
governance. He defines governance as “the complex art of steering multiple agencies, 
institutions and systems which are both operationally autonomous from one another and 
structurally coupled through various forms of reciprocal interdependence” (Jessop, 1997, 
96). For the same author, the process of governance involves the creation of networks 
between actors, organizations and social systems (the economy, the policy, and civil society), 
to negotiate to reach common aims, and to create common languages to interpret the world, 
share some values and so on (Jessop, 1997; Jessop, 1998). 
  We can use Jessop’s governance framework to explain the organization of associations 
with mixed membership in biotechnology.  As we will see, the development of 
biotechnology involves actors with different resources: different researchers have different 
knowledge, industry has the knowledge of the markets and the means to produce goods and 
services, administration has regulatory power and economic resources, and so on. Thus, 
forms of coordination of the actions of the different actors are a requirement for the 
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development of bio-industry. 
3 Characteristics and imperative conditions of bio-industry and bio-policy 
I consider the characteristics of biotechnology research and bio-industry, and what 
imperative conditions they involve for the development of this industry. Then I consider 
the characteristics of the policy that is oriented to the satisfaction of those imperative 
conditions, and what kind of policy-making it requires.  Elaborating on all these 
imperative conditions I consider the number and nature of actors that are engaged in 
biotechnology research, bio-industry and in the policy-making for biotechnology, what 
kinds of relations are involved, and what issues are at stake. I analyze the bibliography 
on the technological characteristics of biotechnology, and the characteristics of bioresearch, 
bio-industry and bio-policy in Japan. In the next section I will consider whether or not 
Japanese associations in bio-industry promote the satisfaction of such imperative 
conditions (Figure 1). 
 
Figure 1: Relation between biotechnology characteristics and associations’ functions 
 
 
 
 
 
 
 
3.1 Characteristics of biotechnology and bio-industry 
The development of biotechnology can be divided in three periods, which can be called the 
pre-scientific period, the traditional biotechnology period, and the modern biotechnology 
period. The prehistory of biotechnology is found in the traditional fermentation industry 
before the 19th century, which produced bread, cheese, beer, and so on. This production 
process was not the application of technologies based on science, but it was based on 
empirical experience without the understanding of the scientific principles, and the 
producer had little control on the production process (Orsenigo, 1989, 33). 
  After this pre-scientific period, traditional biotechnology started in the 19th century 
with Pasteur’s discovery of the implication of microorganisms in fermentation. In this 
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period main innovations were in the fermentation technique. Later, the knowledge on the 
role of bacteria in illness and on the human immunology system let to the application of 
vaccines. Vaccines, glycerol and other products mark the application of large-scale 
fermentation to industries other than food. Since the 1940’s, penicillin fermentation 
allowed the large-scale production of antibiotics, and also, with the improvement of the 
fermentation techniques, amino acids, enzymes, vitamins and other products were 
industrially produced. In the 1960’s continuous large-scale fermentation diffused in the 
industry and proteins were industrially produced (Orsenigo, 1989, 33-36). 
  The third period in the development of biotechnology, or the period in which modern 
biotechnology has been developed, involves techniques other than fermentation. The 
main techniques are cell fusion and DNA modification –recombinant DNA (rDNA) —. The 
rDNA technique has its scientific base in the discovery of the double helix structure of DNA 
in 1953, and was invented in 1973 at two American universities.2) The cell fusion technique 
was invented at a British university in 1975.3) 
  Definitions of biotechnology range from very narrow definitions, which include only the 
techniques of DNA modification, to very wide definitions, which include everything 
involving the use of living organisms for the production of goods and services (Orsenigo, 
1989, 32). The OECD offers a definition that is wide enough to include traditional and 
modern biotechnology, but narrows the concept of biotechnology to only the science-based 
techniques. According to this definition, biotechnology is: “the application of scientific and 
engineering principles to the processing of materials by biological agents to provide goods 
and services” (OECD, 1982, 18).4) Bio-industry consists in the large-scale production of 
                                                          
2) The inventors were Chang and Cohen at Stanford University and Helling at the University of 
California in San Francisco. The technique consists on the introduction of the selected genes from 
one organism in cells of other organisms (Orsenigo, 1989, 37). 
3) The inventor was Kohler at Cambridge University. The technique, also called hybridoma technique, 
consists on the creation of a new cell that mixes the genetic material of two cells. The researcher 
does the fusion of the two cells, but the genetic material mixes naturally (Orsenigo, 1989, 37). 
4) The definition of biotechnology offered by the Japan Bio-industry Association is similar to that of the 
OECD, and includes traditional as well as new biotechnology: "any technique that uses living 
organisms or parts of organisms to make or modify products, to improve plants or animals, or to 
develop microorganisms for specific use" (JBA, 2000). The adoption of a wide definition that 
includes the food and beverages industry that applies fermentation is due to the preponderant 
presence of this industry in Japan. 
 The Japanese government has adopted a narrower definition, considering biotechnology as "modern 
（次頁に続く） 
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goods and services using biotechnology, and their commercialization. From the 1980s, the 
technologies that have experienced greater innovation and multiple applications in 
industry, and have been the object of most public policy for biotechnology, are those 
included in modern biotechnology. 
  Japan is strong in research and industry in the traditional biotechnology,5) especially 
the production of amino acids, nucleic acids, and antibiotics is remarkable. Also the 
production of enzymes, although smaller, is remarkable when considering the impact their 
application has in the production of many processed foods and chemicals. However, in 
products using recombinant techniques, except in the chemical industry, Japan is 
internationally weak (Tsugawa, 1997, 46-49). 
  Orsenigo has described the characteristics of biotechnology using the concept of 
technological regime.6) According to this author biotechnology has the next properties: is a 
science-based technology, is multidisciplinary, has a high degree of technological 
opportunities and uncertainty, and has a low degree of appropriability (Orsenigo, 1989, 
40-49). 
  The development of different techniques in biotechnology is strongly based on scientific 
research. As we have seen, the different technologies have been developing from basic 
research at universities. In addition, the development of genetic engineering has been 
                                                                                                                                                        
biotechnology, which uses the techniques of recombinant DNA, cell fusion, cell cultivation, bioprocess, 
etc. The biotechnology industry is the industry that applies these technologies" (Committee for 
Bio-industry Technology Strategy, 1999). 
5) Before the birth of biotechnology Japan had developed a strong traditional industry of products using 
fermentation, like miso, soy sauce and sake. With the development of biotechnology, traditional 
biotechnology based on fermentations developed further more. For example, the technique of amino 
acid fermentation was invented in Japan in 1956 (Tsugawa, 1997, 46). 
6) Nelson and Winter (1982) elaborated the concept of technological regime in order to study the role of 
technological innovation in economic change. A technological regime is composed by the base 
knowledge, the sources and degree of technological opportunities, and the technological 
appropriability and cumulativeness. The base of knowledge refers to the source (customers and 
suppliers, science and so on) and plurality of knowledge that has been used to create a technology, 
and the ways by which it is acquired. The technological opportunities refer to the facility or 
difficulty to achieve innovations in a specific technology. Appropriability consists on the capacity of 
appropriation of the revenues of innovation by the innovative agent. A low appropriability means 
that the innovation results are public goods.  And, finally, cumulativeness consists on the 
incremental nature of innovation.  Thus, high cumulativeness means that agents who have 
innovated will have more capacity to innovate. A technology with low cumulativeness is that in 
which new-comers have the same possibilities to innovate as previous innovators. 
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possible because of the research on molecular biology at the American National Institutes 
of Health (NIHs). Even more, biotechnology is the result of the combination of knowledge 
from microbiology, biochemistry, genetics, biochemical and chemical engineering, 
electronic engineering, instrumental engineering, and software. Thus, biotechnology is 
strongly science-based and multidisciplinary (Orsenigo, 1989, 40; OECD, 1982, 22-33). 
  The technological opportunities of biotechnology are high because of the novelty and 
the multidisciplinary of this technology. The de-codification of the human genome, which 
is the basis of the medical application of biotechnology, has been completed recently, much 
still remains unknown about existing microorganisms, animals, plants, and their genomes, 
and in the so-called post genome era7) researchers are focusing on the discovery of genes’ 
functions, proteins structure, and proteins functions.  And then, there are huge 
possibilities for the invention of techniques for the application of such discoveries to modify 
and create organisms with characteristics useful in the production of goods and services in 
different industrial sectors. And last, the industrial processes for production at a large 
scale must be created. The range of industries that apply biotechnology is very large. 
These, and some examples of their products, are the chemical industry (amino acids, 
enzymes for detergents, limited enzymes, reagents, polymers, organic acids), electronics 
(biochips, bio-computers, biosensors), the instrumental industry (instruments for 
de-codification of DNA, micro-actuators), environment (dissolution of dioxins), agriculture 
and food (yeast, food additives, genetically modified organisms (GMOs), glucose and 
high-fructose syrups), information (software for de-codification of DNA and for the analysis 
of proteins), energy (biomass, methane, ethanol), and medicine (human insulin, interferon, 
genetic treatment, order made medicines) (METI, 2001a, 2001b; OECD, 1982). In 
addition, due to the high technological opportunities, innovation in biotechnology 
techniques and their application to goods and services are very close (OTA, 1991). 
  However, the feasibility of potential applications of biotechnology, the time required 
for their developement and the economic revenues they could produce are very uncertain. 
This is shown by the difference between different estimates of the world markets for 
biotechnology made by different organisms, and also by the difference between the 
estimates and the actual realizations (Orsenigo, 1989, 43). 
                                                          
7) Post genome era refers to the research that is realized using the results of the genetic decodification, 
and analyzes the functions of genes, and proteins’ structure and functions. 
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  The production at large scale with fermentation requires knowledge based in 
experience, and is difficult to imitate, thus it has a high degree of appropriability by the 
innovator agent of the benefits of innovation. However, the basic science knowledge is 
available to the scientific community, and many products based on techniques different 
from fermentation are easily imitated, thus they have a low appropriability (Orsenigo, 
1989, 44-47). Therefore, patents have come to be an important mechanism to prevent the 
free use of the innovations by agents that have not shared the costs of innovation. 
 
3.2 Imperative conditions of biotechnology and bio-industry 
The characteristics of biotechnology considered above pose some imperative conditions for 
the development of biotechnology research and bio-industry. Because bio-industry is 
strongly based on the development of techniques that are directly based on 
multidisciplinary science, the development of an efficient basic science system is necessary. 
Besides competent scientists and research facilities, a fluid relationship between them is 
fundamental. Scientists in different disciplines, and in public and private research 
centers, have to communicate and exchange knowledge, increase their multidisciplinary 
knowledge and engage in cooperative research projects in order to create new technologies 
based on different disciplines. 
  In addition, since innovation in goods, services and industrial processes depends on 
technological innovation, the close relationship between industry and academia has a 
positive effect on innovation and technology transfer from universities to industry. We 
have seen biotechnology has a high degree of technological opportunities. Scientists and 
managers can engage in knowledge exchange processes in order to match technological 
seeds with industrial needs. To be able to develop these relations, industry and academy 
need a certain degree of mutual knowledge on the industrial and the scientific world, and 
to develop a common language and share some values and aims. In addition, as their 
mutual knowledge and cooperation deepens, their joint capacity to innovate can increase. 
  Since knowledge that can give place to innovation in biotechnology is much diffused, 
and technological opportunities are high, the possibility to create venture companies by the 
researchers who have made an innovation is an important way to develop bio-industry. In 
the country where bio-industry is more developed and competitive, the United States, 62% 
of companies in the biotechnology sector are venture companies. This means that the 
availability of venture capital and a fluid relationship between researchers and venture 
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capitalists are necessary. This also implies that both actors must develop a common 
language and knowledge pool, in order to be able to evaluate the possibilities of the 
innovations. Also their knowledge on patents and the patenting procedures is necessary. 
  In addition, the different industrial sectors exchange their biotechnology related 
products: biochemical products are used in the pharmaceutical, agriculture, food, and 
environment cleaning industries; pharmaceutical products are also used for livestock; 
instrumental, electronics and information industries are the tools for research and the 
production process in other sectors; and the agriculture sector is the source of most of the 
raw materials for biotechnology (OECD, 1982).  Thus, different companies are 
interrelated in the production process, they are interested in securing their exchanges, and 
they can innovate with cooperative research. 
  However, Japan shows important weaknesses in these areas. About basic research, 
Japan shows a shortage of researchers when compared with the US. In 1996 there were 
1,875 graduates and 996 postgraduates in biology in Japan, while in the US they were 
62,081 and 12,009. Also Japan’s basic research is less productive than in the US. 
Between 1992 and 1994 in Japan 8,927 papers on life sciences8) were published, while in 
the US 45,176 papers were published (Bio-Industry Technology Strategy Conference, 1999). 
In addition, the public investment in life sciences-related research is comparatively small 
in Japan. The Japanese government invested 560,000 million yens in 1998, while the US 
government invested 2,080,000 million yens in the same year (Miyata, 2000). 
  The transfer of technology between universities and industry is another week point of 
the Japanese bio-industry. This is showed by the facts that there are few patents held by 
university researchers or shared by researchers and companies, there are very few venture 
companies born from university research, and Japanese companies usually prefer to make 
cooperative research with American universities or to buy their technology rather than to 
make cooperative research with Japanese universities. The causes of these weaknesses 
are found in the lack of venture capital, researchers low mobility, the restrictions on public 
researchers to take other jobs at the same time, the difficulties to get a patent and so on9) 
                                                          
8) Papers on molecular biology, genetics, and microbiology. 
9) Attempting to overcome these weaknesses new polices aiming at structural change have been 
elaborated. In 1998 a law for the establishment of technology-transfer organizations (TLOｓ) was 
passed; in 1999 a law that allows companies to appropriate the intellectual rights of the results of 
research undertaken with public finance (Sangyo katsuryoku saisei tokubetu sochiho), a law that 
（次頁に続く） 
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(Tsugawa, 1997, 47-48; Science and Technology in Japan 1999, 7-8; Kneller, 1999, 415-428; 
saxonhouse, 1986). 
  In conclusion, the development of biotechnology research and bio-industry require the 
promotion of relationships between, and the creation of a pool of knowledge shared by, 
scientists in different disciplines, academia and industry, different companies, and possible 
entrepreneurs and venture capital. However, in Japan there are important deficiencies in 
these areas. 
 
3.3 Characteristics of bio-policy 
3.3.1 Policy for industrial promotion 
The development of the bio-industry sector involves the creation of technologies, based on 
basic research, and their application in the industry for the improvement of industrial 
processes to manufacture conventional products (for example, improving processes of 
traditional fermentation), and for the development of new products. Also, the facilities for 
large-scale industrial production must be provided. And finally the new technologies 
must be safe, and final products must find consumers willing to consume them and not 
distrustful, which implies the formulation of new government regulations. These three 
elements orientate the policy for the promotion of bio-industry, and differentiate it from the 
policies that promoted previous industries.10) 
  Due to the high degree of uncertainty in biotechnology, the Japanese government has 
                                                                                                                                                        
deregulates public researchers' side-jobs, and a law to support new venture business (Chusho kigyo 
gijutsu kakushin seido) were also passed. In addition, the patents law has been revised, an "angel" 
tax system for venture capitalists, two share markets for high technology, and venture funds have 
been established.  However, problems still remain.  For example, in the case of national 
universities, patents are granted either to the individual researcher or to the state, since national 
universities cannot hold patent rights. This discourages research since patenting is too expensive 
for individuals. Also, university researchers' careers depend on the number of published papers, 
and the number of patents held by the researcher is not taken into account. This discourages 
researchers' cooperation with industry and application for patents (Science and Technology in 
Japan, 1999: 7). 
10) These characteristics distinguish bio-policy from the industrial policy in other sectors like, for 
example, iron and steel, which faced problems with the supply of raw materials, energy prices, 
construction of huge and expensive infrastructures, labor relations, overproduction problems, and 
the like (O'Brian, 1994; Yonekura, 1999). Also, in the same sector, the production relationship was 
sequential, not interdependent, and the research and development was more punctual, based on only 
one discipline (engineering), and implying fewer interdependencies among different actors. 
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participated in much research programs. However, because biotechnology affects many 
different industrial sectors, every ministry in Japan has organized its own research 
projects, and has constructed its own facilities and data banks. The government has tried 
to overcome this dispersion with the constitution of the Human Genome Committee in 1990 
to coordinate genomic research (“Science and Technology in Japan, 1992), and with the 
joint elaboration of the “Basic Policy towards the Creation of Biotechnology Industry” by 
the concerned ministries and agencies in 1999. The aims of this plan are the enlargement 
and coordination of the measures for the promotion of basic research and R&D, the 
improvement of the relations between university researchers and industry, the promotion 
of venture capital and technology transfer, and the improvement of the patents system. 
Therefore, coordination of different ministries’ policies is necessary. In the case of Japan, 
the involved ministries are the Ministry of Economy and Industry (METI), the Ministry of 
Education and Technology (MET),11) the Ministry of Health and Welfare (MHW), and the 
Ministry of Agriculture, Forestry and Fisheries (MAFF).  They have established a 
coordinated policy –the Millennium Project (MITI, 2000) — in which there is a common 
program (which represents 21.6% of the project’s budged), and the rest are coordinated, 
although autonomous, programs. 
  In addition, industrial policy for biotechnology crosses, and its success is embedded 
with, other transversal policies.  Since technology transfer is for bio-industry as 
fundamental as raw materials for other industries, regulations that restrict contacts 
between industry and academia,12) or restrict the mobility of researchers, become brakes on 
the development of bio-industry. Also, since the development of biotechnology is based on 
the production of new ideas, and the knowledge and idea-creation capacity are dispersed 
among different researchers, small venture companies become a way for them to convert 
their ideas into products, and at the same time an incentive for invention. Thus, 
                                                          
11) Ministries were reorganized with the administrative reform of 2001. Since January of this year 
the Japan Science and Technology Agency (JSTA) has been incorporated into the Ministry of 
Education (ME), changing its name to the Ministry of Education and Technology (MET). Also, the 
Ministry of International Trade and Industry (MITI) has changed its name to Ministry of Economy 
and Industry (METI). In this paper the abbreviations ME and MITI, or MET and METI are used 
according to the name of the respective ministry in the period concerned. 
12) For example, in Japan, the law restricting the private job of university researchers, and the not 
inclusion of patents got by university researchers in their evaluation, are factors outside the 
industrial policy that affect industrial development. 
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regulations that make start-ups difficult, and insufficient access to venture capital, become 
fundamental problems for the development of bio-industry. Consequently, different 
policies for SMEs, which give financial support, services, and managerial formation to 
entrepreneurs, become fundamental indirect industrial policies for bio-industry. Different 
policies are elaborated and implemented by different agencies, at different territorial levels, 
and with the participation of different industry organizations. All this poses problems of 
coordination. 
 
3.3.2 Regulatory policy for bio-industry 
Regulatory policies affecting not only the access to financial resources, technology transfer, 
and start-ups, but also regulations on patents, safety measures, and commercialization 
rules, have consequences on the development of bio-industry. While in other industries 
the main source of conflict is that between capital and labor, and also between producers in 
cases of overproduction, in bio-industry the main source of conflict lies around the topic of 
patents and intellectual rights, access to research resources, safety, ethics and consumer’s 
right of choice. 
  What can be or not object of a patent, in addition to ethical issues, poses the question of 
the incentive or disincentive effect of patents on research, technology transfer, 
commercialization, and prices. Also, R&D is frequently realized with the participation of 
different actors and finance sources, private and public, consequently the way in which 
benefits are shared can arouse conflicts among the partners. These conflicts can prevent 
research, the sharing of databases, and so on. 
  The discussion on ethics is remarkable on the topics of protection of private 
information and the use of human tissues and biological samples for research and 
production of medical treatments. The regulation of these problems must involve the 
citizens, since without their cooperation no samples would be provided. 
  The safety issue can be divided in three areas. The first one is the safety of the 
facilities for research and industrial production of biotechnology products. This issue 
mainly involves the interests of industry, researchers and the public administration. The 
second issue is the liberation of biotechnology products to the environment. This can be 
for research or for production of biotechnology agriculture products. This issue, in 
addition to researchers, industry, and administration, involves also other stakeholders, like 
the agriculture sector and environmental groups.  The third issue consists on the 
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evaluation and commercialization of biotechnology products. The regulation of this issue, 
in addition to the previous actors, also concerns actors involved in the different moments of 
the commercial process, the general consumer and consumer associations. 
  In addition, the regulation of the safety issues involves problems of competition and 
coordination among the different ministries and agencies regulating biotechnology. This 
is especially remarkable in Japan, where every ministry has established its own 
independent guidelines: The Ministry of Education and Technology regulates universities’ 
research,13) the Ministry of Economy, Trade and Industry regulates the chemical industry, 
the Ministry of Health and Welfare regulates the pharmaceutical industry, and the 
Ministry of Agriculture, Forestry and Fisheries regulates agriculture and food industries. 
 
3.4 Imperative conditions of bio policy-making 
The scientific base of biotechnology implies the need to promote the relationship between 
scientists and the public administration. Since scientists are the agents who have the 
expertise on their discipline, they should participate in science policy making in order to 
make science and research policies efficient. 
  In addition, the applicability of biotechnology to many different industries makes 
necessary the coordination of different ministries in the elaboration of their research 
programs, in order to avoid duplicities, increase the possibility of cooperation among 
researchers in different sectors, and avoid inter-ministerial conflicts due to overlappings 
–this is clear in with the problem of the plurality of safety regulations. Also, every 
industrial sector has its own economic, technological, and public regulation characteristics, 
but all of them share an interest in the development of biotechnologies and their diffusion 
in industry in order to improve production and create new products. Thus, when different 
ministries have a shared strategy for biotechnology, and the different industries in 
biotechnology have also a unified position about their political demands, administration 
and industry can cooperate in policy-making in order to make it more efficient. 
  Finally, when biotechnology products are for the consumer markets, if consumers do 
not accept those products the markets cannot grow. For example, the lack of trust of 
                                                          
13) Before the administrative reform, the Science and Technology Agency had its own guidelines for 
non-university public research centers, and the Ministry of Education had its own guidelines for 
universities' research (Tanaka, 1991, Science and Technology in Japan, 1992). 
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consumers on GMOs has led to their rejection and strict regulation in Japan and Europe. 
For this, it is necessary that public policies guarantee the level of safety that consumers 
demand, the regulation on ethical issues that citizens demand, and the protection of 
privacy of citizens. Also, the advances in bio-medicines and treatments will lead to the 
possibility of avoiding certain gene-related illnesses, the enlargement of life, and even the 
possibility of improvement of individuals’ capacities and/or selection of genetically more 
“suitable” individuals (Fukuyama, 2002). The regulation of these questions should be 
made with the participation of the wide range of affected actors, since there are many 
stakeholders: academy, administration, industry, consumers, citizens, and experts in ethics, 
patients, doctors, and so on. Finally, biomedical research requires the provision of human 
tissues. This involves the regulation of the protection of privacy, informed consent, and 
patents. The regulation of these topics should involve also citizens, who are the main 
affected actors, in addition to doctors, industry, scientists and administration. 
  In conclusion, same as with biotechnology research and industry, public policies for 
biotechnology require the involvement of many different actors, the creation of a common 
pool of knowledge, of a common language, and of consensus on what kind of biotechnology 
is socially desirable. 
4 Associations and their functions 
4.1 Associations in the Japanese bio-industry 
The first association that included biotechnology in its activities was the Japanese 
Association of Industrial Fermentation (JAIF)14), which organized the Bio-Industry 
Development Center (BIDEC) as one of its sections in 1983. This initiative was the 
response to the Ministry of International Trade and Industry’s (MITI) request to create an 
organization in order to assist the ministry’s targeting of biotechnology. In 1987 JAIF and 
BIDEC merged, and became an “incorporated foundation”15) with the name of Japan 
                                                          
14) This association had been founded in 1942 with the aim to promote the production of alcohol during 
the war. 
15) In Japanese, "zaidan hojin". Incorporated foundations and incorporated associations "shadan 
hojin" are organizations that have been recognized by the government as groups of public interest. 
With this recognition they get tax privileges and privileged access to their respective ministry, but 
not to other ministries.  That close relation includes information exchange, participation in 
policy-making and exchange of staff. In addition they have been criticized for becoming a privileged 
destine for retired public officials.  However, the degree of independence of incorporated 
（次頁に続く） 
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Bio-Industry Association (JBA) in 1990. 
  Successively other ministries also targeted biotechnology in their areas, and promoted 
the formation of business associations in biotechnology in order to assist their policies. 
Thus, the Ministry of Agriculture, Forestry and Fisheries (MAFF) promoted the 
“incorporated association” Society for Techno-innovation of Agriculture, Forestry, and 
Fisheries (STAFF) in 1990; and the Ministry of Health and Welfare (MHW) promoted the 
Japan Health Sciences Foundation (JHSF) in 1984 (incorporated in 1986). Also, in the 
pharmaceutical sector, the Japan Pharmaceutical Manufacturers Association (JPMA) had 
already been established in 1968 as a voluntary association16) with the aim of promoting 
research in the pharmaceutical sector, and became interested in biotechnology as a way to 
develop new medicines. In addition, matching with the attempts by regional and local 
administrations to promote bio-industry from the mid-80s, associations at regional level 
were established to promote the relationship between industry, academia and local 
administration, and to promote public acceptance (PA) of biotechnology. 
  In the second half of the 90s two new associations have been established with the 
participation of other of the Japanese bio-industry associations. These new associations 
are the Japan Biological Informatics Consortium (JBIC) and the Japan Association of 
Bio-Industries Executives (JABEX). JBIC is an incorporated association and has the aim 
of promoting bioinformatics17), and JABEX has the aim of lobbying the government for 
policies to promote modern biotechnology. 
 
4.2 Organization and activities of associations 
I analyze the activities of Japanese bio-industry associations in order to make clear the 
functions of these associations and the relationship of these functions with the imperative 
conditions of bio-industry. In order to make this analysis I have surveyed documents of 
the associations and realized interviews with their officials 18) (the results of this analysis 
                                                                                                                                                        
organizations varies case by case, and they are considered to have become more independent from 
the 1980s. 
16) In Japanese, nin-i dantai. Voluntary organizations do not have tax privileges and are more 
independent from the government than the incorporated organizations. 
17) Bioinformatics consists on the combination of information technologies with biotechnology. The 
development of bioinformatics is considered to have been one of the main factors in the rapid 
decodification of the human genome, and to be a fundamental technology for the post genome period. 
18) The analyzed documents are the annual reports, internal rules, public opinions, web pages, and 
（次頁に続く） 
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are shown in Table 1). 
  
1) Japan Bio-Industry Association (JBA) 
JBA is a “public interest foundation” aimed at the promotion of bioscience, biotechnology 
and bio-industry.  About 300 companies, about 100 public organizations and 1,300 
individuals –mostly university researchers— compose its present membership. 
  The Presidency and the Board of Directors compose the Direction organs (50 members). 
There is also an Advisory Committee (54 members). The direction is elected by the 
General Assembly, which is formed by the regular members of JBA. Under the board of 
Directors there is the Secretariat, a research institute and 8 sections, which are composed 
of different subcommittees. 
  The Technology and Information Committee has 5 subcommittees, and its activities 
are the study of the evolution of technology, the evolution of international standardization, 
study of measures for the promotion of venture companies, and discussion of property 
rights regulation, organization of study groups on the future of biotechnology and the 
formulation of proposals to the government.  The Industry-Academia Exchange 
Committee has 8 subcommittees, and promotes the exchange of information and joint study 
of technical topics by industry and university researchers by organizing research groups, 
study meetings, providing research grants, and publishing a magazine. The International 
Affairs Committee has three subcommittees, and its activities are the exchange of 
information and opinions with foreign associations, the realization of surveys abroad, the 
representation of the Japanese bio-industry in international forums, the analysis of 
international regulations, and the submission of opinions on them to the government. The 
Industry and Society Committee has three subcommittees, and promotes public acceptance 
(PA), promotes relations among bio-industry associations and them and the government, 
and organizes symposia, conferences, and surveys.  The Safety and Environment 
Committee, with one subcommittee, analyzes measures of international organizations on 
food safety, on genetically modified organisms (GMOs) safety, and on health care. Also 
studies the effects on bio-industry of the biological arms prohibition treaty, and gives 
opinions to the government. The Biological Resources Research Center makes studies on 
policies on the supply of biological resources, and undertakes public research projects on 
                                                                                                                                                        
reports on the industry and policy. See the sources in the references section. 
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biological resources with the participation of member companies. In addition, in 1999 the 
Biotechnology Industrialization Forum was established with the aim of promoting new 
venture companies in biotechnology. Its activities are the organization of symposiums for 
entrepreneurs, scientists, venture capitalists, technology transfer organizations’ personnel 
(TLO), and so on. In addition, it has organized a committee of senior members of JBA, 
who act as consultants for venture companies. Also, in 1999, 30 chemical companies 
joined in the Green Biotechnology Strategy Forum to discuss a strategy to implement 
biotechnology in the production process in order to reduce the generation of pollution and 
waste. Its activities are the research on technical processes, protection of biomass, 
production of energy from biomass, and the study of environmental problems and of forms 
of international cooperation and regulation of these topics. 
 
2) Society for Techno-Innovation of Agriculture Forestry and Fisheries (STAFF) 
STAFF is a “public interest association” with the aim of promoting biotechnology, and 
technological innovation in general, in the agriculture, forestry and fisheries sectors. 185 
companies, 47 prefectures’ governments, and 13 individuals are members of STAFF. 
  24 members compose the Direction of STAFF, which is elected by STAFF’s Assembly. 
There are also two advisory bodies, with 39 members in total. Under the Direction the 
organizational structure of STAFF is limited to its Secretariat and STAFF’s research 
center, which is undertaking public research on vegetables and animals’ genomes. The 
Secretariat has the Personnel and General Affairs Committee, the Planning and Survey 
Committee, the R&D Committee, which plans and implements R&D projects, and the 
Research Coordination Committee, which coordinates the relationship with the research 
center and undertakes training programs. 
  However, STAFF organizes many less formal committees, ad hoc committees and 
study groups, which are made up by STAFF’s members. The most relevant of these 
committees are as follows. The Publishing Committee is in charge of distributing 
information through the publication of a magazine and other publications.  The 
Experiments Evaluation Committee makes research on GMOs, evaluates experiments 
(made by the association, by its members, or by external organizations) on GMOs, and 
makes surveys on the same area. The Vision Analysis Committee analyzes the technology 
and industrial conditions, and elaborates a strategy for the development of biotechnology in 
the sector. The Research Area Supporting Committees support research through the 
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organization of study meetings, lectures, and so on. And the Management Committee 
organizes activities for the promotion of public acceptance. 
 
3) Japan Human Science Foundation (JHSF) 
JHSF’s objective is to contribute to the improvement of health and welfare, by promoting 
research in basic sciences and technology in the fields of health care, pharmaceuticals, 
medical and health-related devices, and public hygiene. Focusing on the promotion of 
biotechnology, new materials, and other advanced technologies, the Foundation 
interconnects, and promotes collaborative research, between industry, academia, and 
public research centers.  At present 148 companies are members.  They are big 
companies related to the health industry, and include companies from the pharmaceutical, 
chemical, medical materials, food, and fiber industries, 3 banks, and 5 semi-public research 
centers (incorporated associations or foundations). 
  50 members compose the Direction of STAFF. Under the Direction there is the 
Secretariat and two differentiated structures. The General Services Committee and its 
subcommittees compose one structure. All the members of JHSF can participate in these 
subcommittees.  Their activity is oriented to provide services and support to the 
membership for research and development projects. The General Services Committee and 
its Steering Subcommittee are the main committees organizing members’ activities, and 
discussion on general strategies for the sector and the association. Its subcommittees 
analyze and make statements on standards and regulations, represent the Japanese 
medical industry in international discussions on standardization, undertake surveys on 
technology for the medical and food industries, surveys on biological resources, cooperate 
with JHSF’s Health Sciences Resources Bank, organize seminars, symposia, and so on, and 
cooperate with the tasks of the other committees. 
  Three committees and the Health Sciences Research Resources Bank form the other 
structure. These committees depend directly from the Direction and the Secretariat. The 
AIDS Drugs Committee cooperates with the research of the MHW on drugs to combat AIDS. 
The Examination of the Supply of Research Resources Committee (4 subcommittees) 
studies measures for biological resources supply, measures for the utiliztion of the 
Resources Bank, and manages databases. The Joint Research Committee cooperates with 
the research of the Ministry (MHW) by undertaking personnel exchange programs, 
contacting foreign researchers, providing information, organizing the participation of 
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Table 1: Organization and activities of bio-industry associations in Japan 
Associations and their committees Activities 
JBA  
1.Industry-Academia Exchange Committee 
2.Industry and Society Committee 
3.Survey Committees 
4.Biological Resources Research Center 
 
5.Technology and Information Committee 
 
6.International Affairs Committee 
 
7.BIP Forum 
 
8.Safety and Environment Committee 
 
 
9.Green Technology Strategy Forum 
1.Several research groups and study meetings; research grants; magazine. 
2.PA promotion; training; meetings with other groups; seminars at regional level; surveys. 
3.Surveys. 
4.Research on the access to biological resources; coordination of research projects for the 
government. 
5.Analysis of the patent issue; study groups on the future of technology and proposals to 
government; analysis of international standardization; information exchange. 
6.Surveys on foreign biotechnology; participation in international forums; relations with 
foreign biotechnology groups 
7.Support to the creation of venture companies and TLOs through the supply of 
information, advice, and the organization of business meetings and symposia. 
8.Study on the international organizations’ measures on food safety, on GMO safety, on 
health care, and study of the effects of the biological arms prohibition agreement. 
Opinions to the government. 
9.Promotion of green biotechnology through research on technical processes, protection of 
biomass, production of energy from biomass, and the study of environmental problems 
and on the forms of international cooperation and regulation. 
STAFF  
1.Publishing Committee 
2.Vision Analysis Committee 
3.Experiments Evaluation Committee 
4.Survey Committees 
5.Research Area Supporting Committees 
6.Research Coordination Committee 
7.Management Committee 
8.Research Center 
1.Diffusion of information, magazine. 
2.Strategy-making 
3.Research, experiments evaluation and surveys on GMOs. 
4.Surveys. 
5.Support to research, organization of study meetings and lectures. 
6.Evaluation of safety; opinions to government. 
7.PA and consensus conference. 
8.Genome analysis (government project). 
JHSF  
1.General Services Committee 
 
 
 
2.Joint Research Committee 
3.AIDS Drugs Committee 
4.Examination of the Supply of Research 
Resources Committee 
5.Human Science Bank 
1.Elaboration of visions, strategy and internal coordination; political statements; symposia, 
conferences and technology transfer; study of standardization, international 
participation on the discussions on standardization, and political statements; 
participation in the management of the resources bank. 
2.Support to the MHW’s research programs. 
3.Support to the MHW’s research program. 
4.Research on the supply of resources for research. 
 
5.Conservation and supply of human biological resources; ethical evaluation of their use. 
JBIC  
1.SNP Research Center 
2.Japan Biological Research Center 
3.Steering Committee 
 
 
4.Committee for Ethical Examination 
1.Analysis of SNPs (government project). 
2.Planning, standardization, and management of databases. 
3.Strategy-making, think tank, internal information exchange; analysis of intellectual 
property rights issues; analysis of government’s ethical regulations, political statements; 
education, training and surveys. 
4.Ethical evaluation on samples collection for JBIC’s research projects. 
JABEX  
No internal differentiation by committees Formation of consensus among industry, elaboration of political proposals, negotiation 
with government, and promotion of interrelation between government, industry and 
academia. 
JPMA  
1.R&D committee 
 
2.Pharma SNPs consortium 
 
3.Protein Analysis Consortium 
1.Study of political measures for the promotion of technological innovation, and political 
statements; symposia, seminars, and surveys. 
2.Research planning; research on sample standards and sample collection; analysis of 
SNPs and elaboration of databases; ethical evaluation. 
3.Research on proteins structure. 
APBIK  
1.Secretariat 
 
2.Industrialization Committee 
 
3.R&D Committee 
1.Information exchange, lectures, seminars; relation with foreign regional organizations, 
study trips. 
2.Support to SMEs (consultancy), support to venture business creation (advice, assistance 
in finance searching); cooperation in the creation of a venture fund; technology transfer. 
3.Organization of study meetings in order to create new research projects, support to 
cooperative research projects, project evaluation, assistance in the application for public 
subsidies. 
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companies in public research programs, distributing public research subsidies, and so on. 
 
4) Japan Pharmaceutical Manufacturers Association (JPMA) 
JPMA is a voluntary association of pharmaceutical companies oriented to research for 
manufacturing new medicines. Its aim is to promote the interests of the sector, promoting 
the relationship among companies, and defending the sector’s interests in front of the state 
and the society. At present 81 companies are member of JPMA. Its interests go beyond 
the biotechnology field, pointing to the whole environment of the pharmaceutical industry. 
One of its main political objectives is to keep the prices of pharmaceutical products on a 
level that allows companies to invest in research. 19) The areas object of its activity are very 
wide, including standards, training, research and development, public relations, 
international relations, taxes, and so on. JPMA is integrated in the Federation of 
Pharmaceutical Makers Associations of Japan (FPMA).20) 
  In JPMA there are 19 committees and a research center on industrial policy 
(established in 1998). All the committees are integrated under the General Assembly, 
except the Ethical Committee, which is under the Presidency. The relationship is quite 
bottom-up. Except for general services, the committees decide on their activities and 
manage their own budget. The committee most related to biotechnology is the R&D 
Committee, which studies measures and policies for the promotion of technological 
innovation in the pharmaceutical industry. It also organizes surveys, symposia, seminars 
and so on. There are 21 companies participating in the R&D Committee. Although 
JPMA does not undertake research projects by itself, 43 members of JPMA, with the 
support of the R&D Committee, have established two research consortia in order to make 
research in biotechnology. These are the Pharma SNPs Consortium (PSC) and the 
Protein Analysis Consortium. 43 companies that invest 1,000 million in three years for a 
project to analyze the genes related to medicine effects variation compose the PSC. This 
consortium is managed by the Steering Committee, composed by 10 companies, which 
utilizes JPMA headquarters. Its specific activities are the planning of research, research 
on sample standards and sample collections, analysis of SNPs, elaboration of databases, 
                                                          
19) For this reason JPMA has had difficult relationships with the ministry (Howells and Neary, 1991). 
20) In the same Federation there are integrated a total of 12 sectoral associations and 26 regional 
associations of pharmaceutical companies. 
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and ethical evaluation of the research. 
 
5) Japan Biological Informatics Consortium (JBIC) 
12 companies (3 in information technologies and 9 in biotechnology) created a consortium 
in 1998 in order to develop a research project on bioinformatics. The reason to organize 
the consortium was to apply for a government contract for the development of electronic 
commerce, area for which the government had established a specific budget (JBIC, 2001). 
JBIC became an “incorporated association”to the 4 ministries related to biotechnology, in 
the year 2000. JBIC’s aim is to promote the application of information technology in 
biotechnology and bio-industry. At present, 86 big companies, the Japan Foundation for 
Cancer Research, and two individual researchers are members of JBIC. The members 
come, on the one hand, from the field of biotechnology, especially the pharmaceutical 
industry; on the other hand, they come from the information technology, electronic and 
precision instruments industries.  
  25 members, including the Presidency and the Board of Directors, compose the 
Direction of JBIC. The Assembly, formed by the regular members, elects the Direction. 
Under the Presidency there is the Secretariat and 4 sections: the SNPs Research Center, 
the Japan Biological Information Center (JBIRC), the Committee for Ethical Examination, 
and the Steering Committee. Under the Steering Committee there are 6 subcommittees: 
Intellectual Property Rights, Education and Dissemination, Database System, 
Management of SNPs Research Center, R&D, Strategies and Planning. The Intellectual 
Property Rights Committee discusses on this topic, and gives opinions to the government. 
The Education Committee organizes conferences, seminars and so on, in order to increase 
member’s technical knowledge and to disseminate JBIC’s research results. The Data 
Base System Committee establishes plans to develop data systems. The R&D Committee 
prepares specific research projects, and regulates the participation of member companies in 
the research contracted with the government. Finally, the planning committee studies 
and proposes general strategies. 
 
6) Japan Association of Bio-Industries Executives (JABEX) 
JABEX is a business association that represents the industry working with modern 
biotechnology, and acts as think tank and lobby in front of the government and the 
parliament in order to promote modern bio-industry in Japan (Science and Technology in 
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Japan, 1999). 64 company presidents and the presidents of the other 5 main associations 
are the members of JABEX. JABEX has not internal differentiation according to interests 
or tasks. Five members, who are the representatives from the 5 bio-industry associations, 
compose the Presidency. Under the Presidency there is a Board of Directors composed by 
13 members. 
  There have been two causes, which also define JABEX’s activities, of the establishment 
of JABEX. One is the feeling of crisis in the biotechnology sector and the will to formulate 
a general strategy to promote all the sectors. The same day that JABEX was established, 
it submitted its first political proposal: “Creation of the Japanese Biotechnology Industry 
and Strengthening of International Competitiveness. Urgent Proposal.” After this, 
other political statements have followed: “Helix Plan”, “National Strategies on Bio-industry 
Development”, “Opinion on the State of Genetically Modified Foods”, and the proposal of 
industrial policy for biotechnology “b-Japan”. The second reason for the creation of 
JABEX is the need to establish an organization that unifies the opinion of the whole 
bio-industry sector, in order to become the representative of the industry in the 
negotiations with the government, and in order to promote the interrelation between 
government, industry and academia. These aims are pursued with the organization of 
several forums, like the “Life Sciences Summit”, the “Round Table Conference with Five 
Ministers Relevant to Biotechnology and Diet Member’s Promotion Alliance for Life 
Sciences”, and so on. 
 
7) Regional associations – APBIK 
In the second half of the 1980s regional governments and MITI promoted the 
establishment of regional biotechnology promotion associations. This was an attempt to 
promote the establishment of biotechnology industry and research as an economic growth 
engine in the different Prefectures.21) At present, the main regional associations are the 
Hokkaido Bio-Industry Association (HOBIA), Association for the Promotion of Bio-Industry 
in the Kinki Region (APBIK), Association for the Promotion of Bio-Industry in Toyama 
Region (APBIT), Chubu Bio Forum (CBF), Senri Life Science Foundation, Tohoku 
Bio-Industry Promotion Association (TOBIN), Chugoku Bio-Industry Techno Forum, 
                                                          
21) In 1988, MITI had identified 73 of such organizations, most of them established between 1986 and 
1987 (MITI, 1988: 117-123). 
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Shikoku Environment Bio Salon, and Kyushu Industrial Technology Center Bio-Industry 
Forum. In addition there are many other more informal regional “study groups” where 
industry, academia, and local administration join. 
  The main activities of these associations are the promotion of information exchange 
between industry, academia and administration, by organizing conferences, study 
meetings and so on, the collection of data on bio-industry development, and the promotion 
of public acceptance.  However, one of these associations –the Association for the 
Promotion of Bio-Industry in the Kinki Region (APBIK) – has increased its activities, 
focusing now on the promotion of research and development projects, and the promotion of 
technology industrialization and support to venture companies. For this, I consider the 
case of APBIK with more detail. 
  APBIK, with its headquarters in Osaka, was created in 1985 by an initiative of the 
Dean of Osaka University. Its aim was the promotion of the relationship between 
biotechnology industry and researchers in the Kinki region.  At present, APBIK 
undertakes presentation meetings to connect industrial needs with technological seeds, 
cooperates with the formulation of research and development projects by its members, and 
gives assistance to venture companies.  At present, 68 companies, 20 university 
researchers and 20 local administration officials are members of APBIK. 
  Four members, elected by the General Assembly, compose the Presidency. Under the 
Presidency, the Coordinators Committee undertakes the realization of most of APBIK 
activities. This Committee is composed y 10 members and is selected by the Presidency. 
This committee is divided in two subcommittees. The Subcommittee for the Coordination 
of Industrialization organizes conferences, seminars, and so on, in order to promote the 
relationship, collective study and information exchange between industry and academia, 
and provides services for venture companies. It also organizes conferences for the 
presentation of technological seeds. The other subcommittee, the Committee for the 
Making of Research Projects, organizes study meetings oriented to the creation of 
cooperative research projects among the membership, and with other external 
organizations, and also assists them in getting public finance. This committee also 
coordinates the implementation of cooperative research realized by the members. In 
addition, APBIK has promoted, together with the Japan Asia Investment Company and 
METI, the creation of a fund for biotechnology venture companies in the Kinki region, the 
Jaiku Baio Ichigo Investment, which is provided by the business community in the region 
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and by METI. 
 
4.3 Functions of bio-industry associations 
The activities that bio-industry associations undertake can be divided in five groups: think 
tank and educational activities, technology transfer, promotion of members’ research, 
execution of government’s research projects, and representation of the bio-industry. All 
associations realize think tank and educational activities, involving study groups on 
possible evolutions of science and industry, study groups on specific topics, training, 
conferences, surveys, and so on. Associations, except JABEX, also realize technology 
transfer activities, like technological seeds meetings, databases on technological seeds, 
support to matching between companies and researchers, and so forth. Associations, 
except JABEX, promote their members’ research with advising, coordination of cooperative 
research, and assisting in the search of financial sources.  They also undertake 
government’s research programs. The realization of government’s research projects is 
remarkable for the 4 incorporated associations and especially in gene-related research. 
Finally, associations represent the industry in front of the government, society, and foreign 
organizations. This is the main activity of JABEX in front of the government, and the 
incorporated associations do the same in front of their respective ministries. Regional 
associations have a less relevant role in this activity. 
  Considering the effects, or the functions, that these associations’ activities have on the 
bio-industry sector, I conclude that they have three main functions. First, they promote 
the adaptation of the institutional environment to the imperative conditions of 
biotechnology. Associations are developing activities oriented to the improvement of the 
weak points of the Japanese biotechnology. Thus, they press for more public investment 
for the life sciences, for reforms to promote the entrepreneurship of researchers, for policies 
that promote the industry, they also promote the creation of venture capital for 
biotechnology, the creation of TLOs, realize activities for technology transfer, and the like. 
  Second, associations create networks in which industry, academia, administration, and 
financiers can interact. For this, associations use their social capital, which consists on 
their knowledge on what researchers are working on what topics, what companies have 
capabilities on what areas, what officials are in charge of what issues, and then 
associations have the capacity to promote their participation in discussion forums, study 
groups, technology transfer activities, or in specific research projects. 
立命館経営学（第 42巻 第 2号） 110 
  Finally, associations promote collective learning. In the networks and forums that 
associations create, actors from different parts of society (industry, administration, 
academia) and with different resources, needs, values, culture, and the like, join in order to 
exchange opinions, ideas and demands. In this process they share information, increase 
their knowledge on each other and on technological and economic topics, they develop 
cooperative research and so on.  In addition, associations combine in the same 
organization think tank activities and participation in policy making activities. With this, 
the elaboration of strategies for the development of bio-industry and their presentation to 
the administration are developed by the same organization. Therefore, policies for the 
development of bio-industry can incorporate a greater degree of knowledge on the 
objectives and means needed to reach them, and consequently policies can be more 
efficient. 
5 Conclusions 
From the study of the activities of bio-industry associations in Japan I have shown that 
they undertake 3 functions: promote the adaptation of the institutional environment to the 
necessities of bio-industry, promote networking among the stakeholders in bio-industry, 
and promote collective learning.  These functions are different from the functions 
considered in the theory of neocorporatism. For that theory the function of a corporatist 
associational system is to promote social order. However, the problem in bio-industry is 
not a problem of social order, but the necessity to join together dispersed actors with 
complementary resources, and to promote their cooperation in collective learning processes 
and cooperative research. These associations’ functions are promoting the attempts at 
overcoming the weaknesses of the Japanese institutions for the development of 
bio-industry. And they show an evolution of the associational system in order to be more 
functional to the specific characteristics of bio-industry and bio-policy. 
  From these facts we see, on the one hand, the limitations of theory of neocorporatism to 
explain the mixed membership of associations established by industry, academia and 
administration, due to the focus of this theory on conflicting interests and authority 
relations. On the other hand, Jessop’s governance theory offers an explanation that can 
be applied to these mixed membership associations since the focus of the theory is on the 
resource interdependencies among actors and organizations in different social subsystems.  
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